Our Vision

Transforming blood test through technology innovation

As we enter the age of personalized medicine, DNA sequencing is playing an increasingly important role in determining a patient’s optimal treatment plan. Unfortunately, acquiring tumor to sequence often requires performing a tissue biopsy which can be painful, dangerous, and sometimes even impossible, as is the case with both metastatic and early stage cancer. Liquid biopsy, however, offers a viable non-invasive alternative to tissue biopsy. Not only is liquid biopsy minimally stressful for patients, but is also more comprehensive and easily performed at regular intervals. The potential applications of liquid biopsy are vast -- from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening -- and we believe it will play a critical role in the future of cancer management.

核心技术

独创的专利技术*


安可济创新发明的Firefly技术*是一项针对核酸样本尤其是游离DNA(cfDNA) 中罕见或低频突变的检测而研发的全新高通量测序方案,已在美国及中国申请了多项专利*保护。该技术采用“单链环化DNA滚环复制串联重复确认法”,在解决了微量的ctDNA扩增难题的同时极大地提高了检测灵敏度和特异性。

使命愿景

照亮人类攻克癌症的梦想

安可济集团长期致力于通过分子诊断的技术创新,改变目前癌症确诊时已属晚期、5年生存率低的现状,让更多癌症患者能被尽早诊断,获得精准治疗。人体外周血中包含着肿瘤基因变异信息的“循环肿瘤DNA(ctDNA)”成为实现这一理想的一大突破口,目前ctDNA检测对癌症患者的“全病程”管理正变得越来越重要。 

What We Do

Advancing technology

We make necessary technical advancement to a robust assay

Developing clinical tests

We address unmet clinical needs through partnership with research community

Partnering with the leaders

We work with experts to accelerate product development and clinical adoption

技术优势

准确、经济、独创

(1)准确:痕量DNA的转换效率高,因而可准确检测丰度在0.1%及以下的低频突变,分析特异性可达99.99999%。
(2)经济:在达到相同测序精度时的成本较低。
(3)独创:完整的自主知识产权,完全独立的创新研发和专利*申报。

*专利技术(Firefly™技术)
专利名称:用于检测罕见序列变体的组合物和方法
专利号:ZL201410765164.3
专利种类:发明专利

Our Vision

Inventing the future of cancer diagnostics.

For each project we establish relationships with partners who we know will help us create added value for your project. As well as bringing together the public and private sectors, we make sector-overarching links to gather knowledge and to learn from each other. The way we undertake projects is based on permanently applying values that reinforce each other: sociocultural value, experimental value, building-technical value and economical value.

Heading

Our Advantages

Proprietary Technology


AccuraGen uniquely employs rolling-circle amplification to perform consensus-based concatemer error correction. The fundamental of our technology ensures a high conversion rate and minimizes the proliferations of errors.  We optimized our assay to detect a breadth of genetic alterations with a sensitivity approaching the physical limit and a specificity as much as 100x better than benchmark.

Multidisciplinary efforts

Challenging the boundaries, robust results

When our assay is approaching the phsyical limit, we take every bit of efforts to ensure a consistent and robust result. Our multidisciplinary team that spans across mathematics, statistics, computer science, clinical science, genomics, all work together to convert minute of cancer signals in the blood to actionable diagnotics-grade information with meaningful clinical economics.

Our Approach

What We Do

Experiment

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla.

Sequence

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros. Lorem ipsum dolor sit amet consectetur.

Analyze

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare.

Our Advantage

Proprietary on technology.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Successful Properties

Complex process, powerful results.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Meet Our Team

Maecenas egestas arcu quis ligula mattis placerat. Etiam imperdiet imperdiet orci. Praesent nonummy enue habitant morbi.

Learn More
管理团队

董事会

应康

董事会主席

George Cardoza

首席执行官

崔相民

德诚资本创始人兼总经理

Dan Zabrowski

罗氏测序和组织诊断前主管

刘江威

佳辰资本总经理

徐炜

戴勒斯资本执行合伙人

投资机构

加入我们

Latest Publications

Publication of Groundbreaking Study on Ultra-Sensitive Molecular Residual Disease Detection in EMBO Molecular Medicine

The study showed 90% sensitivity and 100% specificity in colorectal cancer patient blood samples collected within six weeks after surgery.

AccuraGen Highlights New Developments in MRD Detection with AccuScan Whole-Genome Sequencing Solution

AccuraGen is gaining attention in the medical community for its innovative approach to minimal residual disease (MRD) detection.

Subscribe to our newsletter now.

Get our news and latest project, first.
In your mailbox. Monthly.

No spam, ever.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form